ACR 61: Congenital Disorders of Glycosylation Awareness Day.
- Session Year: 2017-2018
- House: Assembly
- Latest Version Date: 2017-06-06
This measure would recognize May 16, 2017, as Congenital Disorders of Glycosylation Awareness Day, and commend those medical professionals, researchers, advocates, parents, and families who have committed themselves to better understanding and promoting awareness of congenital disorders of glycosylation.
This measure would recognize May 16, 2017, as Congenital Disorders of Glycosylation Awareness Day, and commend those medical professionals, researchers, advocates, parents, and families who have committed themselves to better understanding and promoting awareness of congenital disorders of glycosylation.
This measure would recognize May 16, 2017, as Congenital Disorders of Glycosylation Awareness Day, and commend those medical professionals, researchers, advocates, parents, and families who have committed themselves to better understanding and promoting awareness of congenital disorders of glycosylation.
WHEREAS, In communities throughout the State of California and the United States of America, many families must endure the suffering of loved ones affected by congenital disorders of glycosylation (CDG); and
WHEREAS, CDG is the umbrella term for a rapidly expanding group of rare genetic, metabolic disorders caused by defects in the bodys complex biochemical process of glycosylation; and
WHEREAS, Glycosylation is the process by which sugar treesglycansare created, altered, and chemically attached to specific proteins and lipids, thereby creating glycoproteins and glycolipids, respectively, which serve numerous important functions in various tissues and organs. Glycosylation involves many different genes in the encoding of numerous varying proteins, including enzymes, and a deficiency or lack of one of these enzymes may lead to various symptoms potentially affecting multiple organ systems; and
WHEREAS, CDG can be associated with a broad range of symptoms and may vary in severity from mild, disabling cases to severe, life-threatening forms. Most often inherited as autosomal recessive conditions, CDG is usually apparent from infancy, with individual disorders representing a mutation to a specific gene; and
WHEREAS, First reported in medical literature by Dr. Jaak Jaeken and his colleagues in 1980, CDG, as a wide-ranging family of disorders, has since expanded to include more than 125 individual disorders, the most commonly diagnosed of which is PMM2-CDG, whose symptoms typically include neurological problems, visual complications, cerebellar hypoplasia, liver disease, kidney cysts, heart abnormalities, diarrhea, and abnormal fat distribution under the skin, among others. Most other forms of CDG cause a similar range of symptoms, with the exception of MPI-CDG, which does not produce neurological problems; and
WHEREAS, CDG affects males and females in equal numbers, and while the exact incidence rate or prevalence of these disorders in the general population remains unknown, with researchers believing that many cases go unrecognized or misdiagnosed, PMM2-CDG alone has been reported in more than 900 individuals; and
WHEREAS, Although not as widespread nor widely understood as other disorders and illnesses, CDG has nonetheless affected many American individuals and their families, and until a cure is found, the responsibility of supporting efforts to provide treatment for those living with any one of these myriad, varying disorders remains of utmost importance; now, therefore, be it
Resolved by the Assembly of the State of California, the Senate thereof concurring, That the Legislature recognizes May 16, 2017, as Congenital Disorders of Glycosylation Awareness Day, and commends those medical professionals, researchers, advocates, parents, and families who have committed themselves to better understanding and promoting awareness of congenital disorders of glycosylation; and be it further
Resolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the Governor and to the author for appropriate distribution.
WHEREAS, In communities throughout the State of California and the United States of America, many families must endure the suffering of loved ones affected by congenital disorders of glycosylation (CDG); and
WHEREAS, CDG is the umbrella term for a rapidly expanding group of rare genetic, metabolic disorders caused by defects in the bodys complex biochemical process of glycosylation; and
WHEREAS, Glycosylation is the process by which sugar treesglycansare created, altered, and chemically attached to specific proteins and lipids, thereby creating glycoproteins and glycolipids, respectively, which serve numerous important functions in various tissues and organs. Glycosylation involves many different genes in the encoding of numerous varying proteins, including enzymes, and a deficiency or lack of one of these enzymes may lead to various symptoms potentially affecting multiple organ systems; and
WHEREAS, CDG can be associated with a broad range of symptoms and may vary in severity from mild, disabling cases to severe, life-threatening forms. Most often inherited as autosomal recessive conditions, CDG is usually apparent from infancy, with individual disorders representing a mutation to a specific gene; and
WHEREAS, First reported in medical literature by Dr. Jaak Jaeken and his colleagues in 1980, CDG, as a wide-ranging family of disorders, has since expanded to include more than 125 individual disorders, the most commonly diagnosed of which is PMM2-CDG, whose symptoms typically include neurological problems, visual complications, cerebellar hypoplasia, liver disease, kidney cysts, heart abnormalities, diarrhea, and abnormal fat distribution under the skin, among others. Most other forms of CDG cause a similar range of symptoms, with the exception of MPI-CDG, which does not produce neurological problems; and
WHEREAS, CDG affects males and females in equal numbers, and while the exact incidence rate or prevalence of these disorders in the general population remains unknown, with researchers believing that many cases go unrecognized or misdiagnosed, PMM2-CDG alone has been reported in more than 900 individuals; and
WHEREAS, Although not as widespread nor widely understood as other disorders and illnesses, CDG has nonetheless affected many American individuals and their families, and until a cure is found, the responsibility of supporting efforts to provide treatment for those living with any one of these myriad, varying disorders remains of utmost importance; now, therefore, be it
Resolved by the Assembly of the State of California, the Senate thereof concurring, That the Legislature recognizes May 16, 2017, as Congenital Disorders of Glycosylation Awareness Day, and commends those medical professionals, researchers, advocates, parents, and families who have committed themselves to better understanding and promoting awareness of congenital disorders of glycosylation; and be it further
Resolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the Governor and to the author for appropriate distribution.
WHEREAS, In communities throughout the State of California and the United States of America, many families must endure the suffering of loved ones affected by congenital disorders of glycosylation (CDG); and
WHEREAS, CDG is the umbrella term for a rapidly expanding group of rare genetic, metabolic disorders caused by defects in the bodys complex biochemical process of glycosylation; and
WHEREAS, Glycosylation is the process by which sugar treesglycansare created, altered, and chemically attached to specific proteins and lipids, thereby creating glycoproteins and glycolipids, respectively, which serve numerous important functions in various tissues and organs. Glycosylation involves many different genes in the encoding of numerous varying proteins, including enzymes, and a deficiency or lack of one of these enzymes may lead to various symptoms potentially affecting multiple organ systems; and
WHEREAS, CDG can be associated with a broad range of symptoms and may vary in severity from mild, disabling cases to severe, life-threatening forms. Most often inherited as autosomal recessive conditions, CDG is usually apparent from infancy, with individual disorders representing a mutation to a specific gene; and
WHEREAS, First reported in medical literature by Dr. Jaak Jaeken and his colleagues in 1980, CDG, as a wide-ranging family of disorders, has since expanded to include more than 125 individual disorders, the most commonly diagnosed of which is PMM2-CDG, whose symptoms typically include neurological problems, visual complications, cerebellar hypoplasia, liver disease, kidney cysts, heart abnormalities, diarrhea, and abnormal fat distribution under the skin, among others. Most other forms of CDG cause a similar range of symptoms, with the exception of MPI-CDG, which does not produce neurological problems; and
WHEREAS, CDG affects males and females in equal numbers, and while the exact incidence rate or prevalence of these disorders in the general population remains unknown, with researchers believing that many cases go unrecognized or misdiagnosed, PMM2-CDG alone has been reported in more than 900 individuals; and
WHEREAS, Although not as widespread nor widely understood as other disorders and illnesses, CDG has nonetheless affected many American individuals and their families, and until a cure is found, the responsibility of supporting efforts to provide treatment for those living with any one of these myriad, varying disorders remains of utmost importance; now, therefore, be it
Resolved by the Assembly of the State of California, the Senate thereof concurring, That the Legislature recognizes May 16, 2017, as Congenital Disorders of Glycosylation Awareness Day, and commends those medical professionals, researchers, advocates, parents, and families who have committed themselves to better understanding and promoting awareness of congenital disorders of glycosylation; and be it further
Resolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the Governor and to the author for appropriate distribution.
|
Date
|
Status
|
|---|---|
| Jun 6, 2017 | Chaptered by Secretary of State - Res. Chapter 68, Statutes of 2017. |
| Jun 6, 2017 | Enrolled and filed with the Secretary of State at 11 a.m. |
| May 31, 2017 | In Assembly. Ordered to Engrossing and Enrolling. |
| May 30, 2017 | Adopted and to Assembly. (Ayes 40. Noes 0. Page 1280.) |
| May 26, 2017 | Ordered to special consent calendar. |
| May 24, 2017 | From committee: Ordered to third reading. |
| May 16, 2017 | In Senate. To Com. on RLS. |
| May 15, 2017 | Coauthors revised. |
| May 1, 2017 | From committee: Be adopted. Ordered to Third Reading. (Ayes 10. Noes 0.) (May 1). |
| Apr 24, 2017 | Referred to Com. on RLS. |
| Apr 19, 2017 | From printer. |
| Apr 18, 2017 | Introduced. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| May 30, 2017 | Special Consent Calendar # ACR61 Nazarian et al. | Senate Floor |
Passed |
|
| May 1, 2017 | Be adopted. To third reading. | Assembly Standing Committee on Rules |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | ACR 61 |
THIRD READING
Bill No: ACR 61
Introduced: 4/18/17
ASSEMBLY FLOOR: Read and adopted, 5/15/17
SUBJECT: Congenital Disorders of Glycosylation Awareness Day
DIGEST:
This resolution recognizes May 16, 2017, as Congenital Disorders of Glycosylation Awareness Day, and commends those medical professionals, researchers, advocates, parents, and families who have committed themselves to better understanding and promoting awareness of congenital disorders of glycosylation.
ANALYSIS: This resolution makes the following legislative findings:
- Congenital disorders of glycosylation (CDG) is the umbrella term for a rapidly expanding group of rare genetic, metabolic disorders caused by defects in the body’s complex biochemical process of glycosylation.
- CDG can be associated with a broad range of symptoms and may vary in severity from mild, disabling cases to severe, life-threatening forms. Most often inherited as autosomal recessive conditions, CDG is usually apparent from infancy, with individual disorders representing a mutation to a specific gene.
- First reported in medical literature by Dr. Jaak Jaeken and his colleagues in 1980, CDG, as a wide-ranging family of disorders, has since expanded to include more than 125 individual disorders, the most commonly diagnosed of which is PMM2-CDG, whose symptoms typically include neurological problems, visual complications, cerebellar hypoplasia, liver disease, kidney cysts, heart abnormalities, diarrhea, and abnormal fat distribution under the skin, among others. Most other forms of CDG cause a similar range of symptoms, with the exception of MPI-CDG, which does not produce neurological problems.
- CDG affects males and females in equal numbers, and while the exact incidence rate or prevalence of these disorders in the general population remains unknown, with researchers believing that many cases go unrecognized or misdiagnosed, PMM2-CDG alone has been reported in more than 900 individuals.
This resolution recognizes May 16, 2017, as Congenital Disorders of Glycosylation Awareness Day, and commends those medical professionals, researchers, advocates, parents, and families who have committed themselves to better understanding and promoting awareness of congenital disorders of glycosylation.
FISCAL EFFECT: Appropriation: No Fiscal Com.: No Local: No
None received
OPPOSITION: (Verified 5/24/17)
None received
Prepared by: Karen Chow / SFA / (916) 651-1520
5/25/17 9:39:35
**** END ****
ASSEMBLY THIRD READING
ATR Bill Id:ACR 61
Author:(Nazarian)
As Introduced Ver:April 18, 2017
Majority vote
Committee | Votes | Ayes | Noes |
Rules | 10-0 | Cooley, Brough, Cervantes, Chen, Friedman, Grayson, Levine, Nazarian, Salas, Waldron |
SUMMARY: Recognizes May 16, 2017, as Congenital Disorders of Glycosylation Awareness Day, and commends those medical professionals, researchers, advocates, parents, and families who have committed themselves to better understanding and promoting awareness of congenital disorders of glycosylation. Specifically, this resolution makes the following legislative findings:
- Throughout the State of California and the United States, many families must endure the suffering of loved ones affected by congenital disorders of glycosylation (CDG).
- CDG is the umbrella term for a rapidly expanding group of rare genetic, metabolic disorders caused by defects in the body’s complex biochemical process of glycosylation.
- Glycosylation is the process by which "sugar trees," glycans, are created, altered, and chemically attached to specific proteins and lipids, thereby creating glycoproteins and glycolipids, respectively, which serve numerous important functions in various tissues and organs. Glycosylation involves many different genes in the encoding of numerous varying proteins, including enzymes, and a deficiency or lack of one of these enzymes may lead to various symptoms potentially affecting multiple organ systems.
- CDG can be associated with a broad range of symptoms and may vary in severity from mild, disabling cases to severe, life-threatening forms. Most often inherited as autosomal recessive conditions, CDG is usually apparent from infancy, with individual disorders representing a mutation to a specific gene.
- Dr. Jaak Jaeken and his colleagues first reported CDG in medical literature in 1980, as a wide-ranging family of disorders. CDG has since expanded to include more than 125 individual disorders, the most commonly diagnosed of which is PMM2-CDG, whose symptoms typically include neurological problems, visual complications, cerebellar hypoplasia, liver disease, kidney cysts, heart abnormalities, diarrhea, and abnormal fat distribution under the skin, among others.
- CDG affects males and females in equal numbers, and while the exact incidence rate or prevalence of these disorders in the general population remains unknown, with researchers believing that many cases go unrecognized or misdiagnosed, PMM2-CDG alone has been reported in more than 900 individuals.
- Although not as widespread nor widely understood as other disorders and illnesses, CDG has nonetheless affected many American individuals and their families. Until a cure is found, the responsibility of supporting efforts to provide treatment for those living with any one of these myriad, varying disorders remains of utmost importance.
FISCAL EFFECT: None
Analysis Prepared by: Nicole Willis / RLS. / (916) 319-2800 FN: 0000214
Date of Hearing: May 1, 2017
ASSEMBLY COMMITTEE ON
, Chair
ABPCA Bill Id:
Author:() – As Ver:
SUBJECT:
SUMMARY: Recognizes May 16, 2017, as Congenital Disorders of Glycosylation Awareness Day, and commends those medical professionals, researchers, advocates, parents, and families who have committed themselves to better understanding and promoting awareness of congenital disorders of glycosylation. Specifically, this resolution makes the following legislative findings:
- Throughout the State of California and the United States, many families must endure the suffering of loved ones affected by congenital disorders of glycosylation (CDG).
- CDG is the umbrella term for a rapidly expanding group of rare genetic, metabolic disorders caused by defects in the body’s complex biochemical process of glycosylation.
- Glycosylation is the process by which “sugar trees,” glycans, are created, altered, and chemically attached to specific proteins and lipids, thereby creating glycoproteins and glycolipids, respectively, which serve numerous important functions in various tissues and organs. Glycosylation involves many different genes in the encoding of numerous varying proteins, including enzymes, and a deficiency or lack of one of these enzymes may lead to various symptoms potentially affecting multiple organ systems.
- CDG can be associated with a broad range of symptoms and may vary in severity from mild, disabling cases to severe, life-threatening forms. Most often inherited as autosomal recessive conditions, CDG is usually apparent from infancy, with individual disorders representing a mutation to a specific gene.
- Dr. Jaak Jaeken and his colleagues first reported CDG in medical literature in 1980, as a wide-ranging family of disorders. CDG has since expanded to include more than 125 individual disorders, the most commonly diagnosed of which is PMM2-CDG, whose symptoms typically include neurological problems, visual complications, cerebellar hypoplasia, liver disease, kidney cysts, heart abnormalities, diarrhea, and abnormal fat distribution under the skin, among others.
- CDG affects males and females in equal numbers, and while the exact incidence rate or prevalence of these disorders in the general population remains unknown, with researchers believing that many cases go unrecognized or misdiagnosed, PMM2-CDG alone has been reported in more than 900 individuals.
- Although not as widespread nor widely understood as other disorders and illnesses, CDG has nonetheless affected many American individuals and their families. Until a cure is found, the responsibility of supporting efforts to provide treatment for those living with any one of these myriad, varying disorders remains of utmost importance.
FISCAL EFFECT: None
REGISTERED SUPPORT / OPPOSITION:
Support
None on file
Opposition
None on file
Analysis Prepared by:
Bill Author
Bill Co-Author(s):